Answers are grounded in this paper and cite their sources.
Summary: Patients with active myeloma, especially with earlier stages of the disease, are susceptible to COVID-19 infection and can have adverse outcomes, even in those on first-line treatment. Importantly, myeloma therapy can be safely administered, and optimal control of myeloma is associated with improved outcome. See related video: https://vimeo.com/486246183/559a80cfae See related article by Hultcrantz et al., p. 234.
No takes yet. Share an insight, caveat, or question.
A 2020 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: